ArticleThe American journal of case reports2025
Atorvastatin-Associated Acute Pancreatitis: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Study on the Mechanism by Which Atorvastatin Enhances the Stability of Atherosclerotic Plaques in ApoESichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.Frontiers in drug safety and regulation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Acute pancreatitis (AP) occurs when pancreatic enzymes activate within the pancreas, causing damage. In the USA, 210 000 patients are hospitalized annually due to AP. Although statin-induced pancreatitis is rare and often misdiagnosed, it is crucial to investigate, as avoiding the causative medication can prevent attacks. There is conflicting evidence, and further research is needed to determine if statins increase the risk of AP. CASE REPORT In this report, we detail the case of a 48-year-old man with a history of dyslipidemia, for which he was prescribed atorvastatin 40 mg/day as a lipid-lowering agent. He developed acute pancreatitis after using atorvastatin. He initially presented to the emergency room with worsening epigastric pain. Elevated levels of lipase, amylase, and alanine aminotransferases in laboratory tests indicated acute pancreatitis. Given these findings, supportive care was promptly initiated, and atorvastatin, identified as the potential trigger, was discontinued. Notably, the patient had no history of alcohol or tobacco use, and extensive diagnostic efforts ruled out other common causes of acute pancreatitis. The absence of other risk factors reinforced the likelihood that atorvastatin was responsible for his condition, as noted in Table 2. This case underscores the importance of careful monitoring of symptoms and laboratory findings in patients treated with statin medications, particularly when prescribed for dyslipidemia. CONCLUSIONS Documenting such unusual cases could help highlight the potential risks of acute pancreatitis associated with statin use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.